(-)-(1R)-5',11'-dihydro-3H-spiro[cyclopentane-1,10'-dibenzo-[a,d]cyclohepten]-3-one | 1111640-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: (-)-(1R)-5',11'-dihydro-3H-spiro[cyclopentane-1,10'-dibenzo-[a,d]cyclohepten]-3-one
• 英文别名: (3R)-spiro[cyclopentane-3,9'-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene]-1-one
• CAS: 1111640-43-7
• 化学式: C₁₉H₁₈O
• 分子量: 262.351
• InChiKey: ZCXCCHRKHAXWIW-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (-)-(1R)-5',11'-dihydro-3H-spiro[cyclopentane-1,10'-dibenzo-[a,d]cyclohepten]-3-one 、 3-氨基丙酸甲酯盐酸盐 在 溶剂黄146 、 N,N-二异丙基乙胺 、 sodium cyanoborohydride 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 50.0h， 以21 mg的产率得到methyl N-((1R)-5',11'-dihydrospiro[cyclopentane-1,10'-dibenzo[a,d]cyclohepten]-3-yl)-β-alaninate
  参考文献：
  名称：

  Novel Spirotetracyclic Zwitterionic Dual H₁/5-HT_2A Receptor Antagonists for the Treatment of Sleep Disorders

  摘要：

  Histamine H-1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H-1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9'a, a novel spirotetracyclic compound endowed with good H-1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H-1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3-10 mg/kg po.

  DOI：

  10.1021/jm100856p
• 作为产物：
  描述：

  5',11'-dihydro-3H-spiro[cyclopentane-1,10'-dibenzo[a,d]cyclohepten]-3-one 在 Chiralpak IA 作用下， 以 甲醇 、 乙醇 、 正己烷 为溶剂， 以683 mg的产率得到(-)-(1R)-5',11'-dihydro-3H-spiro[cyclopentane-1,10'-dibenzo-[a,d]cyclohepten]-3-one
  参考文献：
  名称：

  Novel Spirotetracyclic Zwitterionic Dual H₁/5-HT_2A Receptor Antagonists for the Treatment of Sleep Disorders

  摘要：

  Histamine H-1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H-1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9'a, a novel spirotetracyclic compound endowed with good H-1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H-1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3-10 mg/kg po.

  DOI：

  10.1021/jm100856p

文献信息

• Novel Spirotetracyclic Zwitterionic Dual H₁/5-HT_2A Receptor Antagonists for the Treatment of Sleep Disorders
  作者：Massimo Gianotti、Maurizio Botta、Stephen Brough、Renzo Carletti、Emiliano Castiglioni、Corrado Corti、Michele Dal-Cin、Sonia Delle Fratte、Denana Korajac、Marija Lovric、Giancarlo Merlo、Milan Mesic、Francesca Pavone、Laura Piccoli、Slavko Rast、Maja Roscic、Anna Sava、Mario Smehil、Luigi Stasi、Andrea Togninelli、Mark J. Wigglesworth

  DOI：10.1021/jm100856p

  日期：2010.11.11

  Histamine H-1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H-1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9'a, a novel spirotetracyclic compound endowed with good H-1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H-1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3-10 mg/kg po.